drugset / Trial / NCT04014101
SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label#single center #non-randomized #Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with advanced stage hepatocellular carcinoma.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2019-10-01
- Completion
- 2020-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | — | Oral |